000			01937 a2200541 4500
005			20250517031245.0
264		0	_c20160512
008			201605s 0 0 eng d
022			_a1573-0646
024	7		_a10.1007/s10637-015-0242-6 _2doi
040			_aNLM _beng _cNLM
100	1		_aGarcia-Manero, Guillermo
245	0	0	_aPhase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. _h[electronic resource]
260			_bInvestigational new drugs _cAug 2015
300			_a870-80 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAminopyridines _xadverse effects
650	0	4	_aAntineoplastic Agents _xadverse effects
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols
650	0	4	_aAurora Kinases _xantagonists & inhibitors
650	0	4	_aAzacitidine _xadverse effects
650	0	4	_aFemale
650	0	4	_aHematologic Neoplasms _xdrug therapy
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMaximum Tolerated Dose
650	0	4	_aPhenylurea Compounds _xadverse effects
650	0	4	_aProtein Kinase Inhibitors _xadverse effects
650	0	4	_aReceptors, Vascular Endothelial Growth Factor
700	1		_aTibes, Raoul
700	1		_aKadia, Tapan
700	1		_aKantarjian, Hagop
700	1		_aArellano, Martha
700	1		_aKnight, Emily A
700	1		_aXiong, Hao
700	1		_aQin, Qin
700	1		_aMunasinghe, Wijith
700	1		_aRoberts-Rapp, Lisa
700	1		_aAnsell, Peter
700	1		_aAlbert, Daniel H
700	1		_aOliver, Brian
700	1		_aMcKee, Mark D
700	1		_aRicker, Justin L
700	1		_aKhoury, Hanna Jean
773	0		_tInvestigational new drugs _gvol. 33 _gno. 4 _gp. 870-80
856	4	0	_uhttps://doi.org/10.1007/s10637-015-0242-6 _zAvailable from publisher's website
999			_c24861417 _d24861417